Publication: Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues
Issued Date
2014-05-16
Resource Type
ISSN
10902104
0006291X
0006291X
Other identifier(s)
2-s2.0-84900453976
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemical and Biophysical Research Communications. Vol.447, No.4 (2014), 580-585
Suggested Citation
Tanwarat Sanvoranart, Aungkura Supokawej, Pakpoom Kheolamai, Yaowalak U-Pratya, Nuttha Klincumhom, Sirikul Manochantr, Methichit Wattanapanitch, Surapol Issaragrisil Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochemical and Biophysical Research Communications. Vol.447, No.4 (2014), 580-585. doi:10.1016/j.bbrc.2014.04.044 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33263
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues
Other Contributor(s)
Abstract
Bortezomib (BZB) is a chemotherapeutic agent approved for treating multiple myeloma (MM) patients. In addition, there are several reports showing that bortezomib can induce murine mesenchymal stem cells (MSCs) to undergo osteogenic differentiation and increase bone formation in vivo. MSCs are the multipotent stem cells that have capacity to differentiate into several mesodermal derivatives including osteoblasts. Nowadays, MSCs mostly bone marrow derived have been considered as a valuable source of cell for tissue replacement therapy. In this study, the effect of bortezomib on the osteogenic differentiation of human MSCs derived from both bone marrow (BM-MSCs) and postnatal sources such as placenta (PL-MSCs) were investigated. The degree of osteogenic differentiation of BM-MSCs and PL-MSCs after bortezomib treatment was assessed by alkaline phosphatase (ALP) activity, matrix mineralization by Alizarin Red S staining and the expression profiles of osteogenic differentiation marker genes, Osterix, RUNX2 and BSP. The results showed that 1 nM and 2 nM BZB can induce osteogenic differentiation of BM-MSCs and PL-MSCs as demonstrated by increased ALP activity, increased matrix mineralization and up-regulation of osteogenic differentiation marker genes, Osterix, RUNX2 and BSP as compared to controls. The enhancement of osteogenic differentiation of MSCs by bortezomib may lead to the potential therapeutic applications in human diseases especially patients with osteopenia. © 2014 Elsevier Inc. All rights reserved.